Biotechnology
OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002
SEOUL, South Korea, Nov. 13, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed uncanny clinical findings from a multi-center Phase 2a trial with Nav1.7 selective OLP-1002 in osteoarthritis (OA) patients with moderate to severe pain inAustralia with Novotech...
2023-11-13 22:00
1362
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Bylvay (odevixibat) is the first and only oral treatment available in Canada
for the treatment of pruritus due to this rare genetic condition
ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ -- Today, Ipsen
2023-11-13 20:20
1316
Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery
MELBOURNE, Australia and PARIS, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) andParis-based Mauna Kea Technologies (Euronext Growth: ALMKT,Mauna Kea), today announce an expansion of the IRiS (Imaging and Robotics in Surgery) Alliance[1] through a stra...
2023-11-13 16:27
1499
Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates
CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, today announced that it has entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next-gener...
2023-11-13 16:04
1341
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB
HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB), and abst...
2023-11-13 08:10
2374
First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591
MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio...
2023-11-13 07:38
1434
Fapon Inaugurates State-of-the-Art R&D Center in Lexington, MA
LEXINGTON, Mass., Nov. 11, 2023 /PRNewswire/ -- Fapon, a global leading life sciences organization, is thrilled to announce the grand opening of its US-based Research and Development (R&D) Center, strategically located in Lexington, Massachusetts. This Center represents Fapon's unwavering commitme...
2023-11-11 20:36
3087
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results
SHENZHEN, China, Nov. 9, 2023 /PRNewswire/ -- On November 9, 2023, ImmVira announced the successful completion of Phase I clinical study conducted on late-stage patients with various tumor types for our intravenous oncolytic product, MVR-T3011 IV, inthe United States. This milestone was marked by...
2023-11-10 08:00
1869
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data
* Safety Review Committee evaluated dose level 1 safety data of PMC-403 and approved advancing to the higher dose treatment. * The starting dose (0.7mg) of PMC-403 showed potential in improving eyesight for neovascular age-related macular degeneration patients with suboptimal response to cur...
2023-11-09 21:00
1479
TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS
Jaime Arango, Chief Financial Officer, Jens Schröder as Chief Medical Officer
andRachel Mooney, Chief Communications Officer
BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics
2023-11-09 19:01
3290
European Wellness and DXN Sign MoU to Establish World-Class Wellness Centre!
CYBERJAYA, Malaysia, Nov. 9, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) has signed a Memorandum of Understanding with DXN Holdings Berhad (DXN) to jointly develop and establish a comprehensive wellness centre that draws from the extensive expertise and experience of both p...
2023-11-09 11:46
2647
DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells
Feasibility Project Awarded VA Technology Transfer Program BRAVE Funding SALT LAKE CITY, Nov. 9, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function...
2023-11-09 08:15
1991
Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023
HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr.Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held atBoston, Unit...
2023-11-09 08:10
4635
WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan
SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, recei...
2023-11-09 08:00
2034
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology
TAIPEI, Nov. 8, 2023 /PRNewswire/ -- * AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of doses of 0.5, 1, 2, and 4 mg in DME patients. * Data combining all 4 cohorts showed mean improvement in Best Corrected Visual Acc...
2023-11-08 23:23
1926
Porton Advanced Announces a Strategic Partnership with BioMap, with AI Models Facilitating AAV Gene Therapy Development
SUZHOU, China, Nov. 8, 2023 /PRNewswire/ -- On November 8, 2023, Porton Advanced announced the establishment of a strategic partnership with BioMap. BioMap will leverage Porton Advanced's unique Adeno-Associated Virus (AAV) vector technology platform and research data to develop AAV assembly effi...
2023-11-08 22:31
2197
Complete Genomics' DNBSEQ-T20x2RS* Named "Next Generation Sequencing Solution of the Year" by 2023 BioTech Breakthrough Awards Program
Third Annual Awards Program Recognizes Innovation in the Global Life Sciences
and Biotechnology Industry
SAN JOSE, Calif., Nov. 8, 2023 /PRNewswire/ -- Complete Genomics,
2023-11-08 22:00
2085
WuXi Biologics Receives AAA MSCI ESG Rating
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings, the highest rating for compan...
2023-11-08 08:30
1556
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs
* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor). * The vir...
2023-11-08 08:30
1903
Flagship Pioneering Expands into Asia-Pacific Region, with Regional Hub in Singapore
André Andonian Joins Flagship to Lead APAC Region SINGAPORE, Nov. 8, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced its expansion into theAsia-Pacific region, with the opening of a regional hub inSingapore. This follows the company's expansion into ...
2023-11-08 06:00
1967
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7120
